BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer
BridgeBio Pharma (Nasdaq: BBIO) has appointed Thomas Trimarchi, Ph.D., as President and Chief Operating Officer (COO), effective immediately. In this newly created role, Dr. Trimarchi will drive operational excellence, strategic planning, and overall business success, reporting directly to CEO Neil Kumar, Ph.D. He will lead cross-functional activities to develop a centralized operation across the late-stage pipeline, focusing on efficiency, rigor, and scale.
Dr. Trimarchi, who joined BridgeBio in 2018, previously served as Chief Product Officer and is a board member of ML Bio Solutions, a BridgeBio affiliate. His prior experience includes roles at Regeneron Pharmaceuticals and Goldman Sachs. CEO Kumar praised Trimarchi's patient-first approach and data-driven decision-making, expressing excitement about the continued growth and impact on patients under his leadership.
BridgeBio Pharma (Nasdaq: BBIO) ha nominato Thomas Trimarchi, Ph.D., come Presidente e Direttore Operativo (COO), con effetto immediato. In questo nuovo ruolo, il Dr. Trimarchi guiderà l'eccellenza operativa, la pianificazione strategica e il successo complessivo dell'azienda, riportando direttamente al CEO Neil Kumar, Ph.D. Dirigerà attività interfunzionali per sviluppare un'operazione centralizzata lungo il portafoglio di progetti in fase avanzata, concentrandosi su efficienza, rigorosità e scala.
Il Dr. Trimarchi, che è entrato in BridgeBio nel 2018, ha precedentemente ricoperto il ruolo di Chief Product Officer ed è membro del consiglio di ML Bio Solutions, un affiliato di BridgeBio. La sua esperienza precedente include ruoli presso Regeneron Pharmaceuticals e Goldman Sachs. Il CEO Kumar ha elogiato l'approccio orientato al paziente del Trimarchi e le decisioni basate sui dati, esprimendo entusiasmo per la continua crescita e l'impatto sui pazienti sotto la sua guida.
BridgeBio Pharma (Nasdaq: BBIO) ha nombrado a Thomas Trimarchi, Ph.D., como Presidente y Director de Operaciones (COO), con efecto inmediato. En este nuevo rol, el Dr. Trimarchi llevará a cabo la excelencia operativa, la planificación estratégica y el éxito general del negocio, reportando directamente al CEO Neil Kumar, Ph.D. Dirigirá actividades interfuncionales para desarrollar una operación centralizada a lo largo de la cartera de proyectos en fase tardía, enfocándose en la eficiencia, el rigor y la escala.
El Dr. Trimarchi, quien se unió a BridgeBio en 2018, se desempeñó anteriormente como Director de Productos y es miembro de la junta de ML Bio Solutions, una afiliada de BridgeBio. Su experiencia previa incluye roles en Regeneron Pharmaceuticals y Goldman Sachs. El CEO Kumar elogió el enfoque centrado en el paciente de Trimarchi y la toma de decisiones basada en datos, expresando entusiasmo por el crecimiento continuo y el impacto en los pacientes bajo su liderazgo.
브릿지바이오 파마(나스닥: BBIO)가 토마스 트리마르키(Ph.D.)를 사장 겸 최고운영책임자(COO)로 즉각 임명했습니다. 이로써 새로운 역할에서 트리마르키 박사는 운영의 우수성, 전략적 계획 수립 및 전반적인 비즈니스 성공을 이끌고, CEO 닐 쿠마르(Ph.D.)에게 직접 보고하게 됩니다. 그는 효율성, 엄격함, 규모에 중점을 두고 후기 단계 파이프라인을 통해 중앙 집중식 운영을 개발하기 위해 여러 기능 간 활동을 주도할 것입니다.
트리마르키 박사는 2018년에 브릿지바이오에 합류했으며, 이전에는 최고제품책임자(CPO)로 재직하였고 브릿지바이오의 자회사인 ML 바이오 솔루션의 이사도 활동하고 있습니다. 그의 이전 경력으로는 레제너론 제약과 골드만 삭스에서 근무한 경험이 있습니다. 쿠마르 CEO는 트리마르키의 환자 중심 접근법과 데이터 기반 의사결정을 칭찬하며 그의 리더십 아래 지속적인 성장과 환자에게 미치는 영향을 기대한다고 밝혔습니다.
BridgeBio Pharma (Nasdaq: BBIO) a nommé Thomas Trimarchi, Ph.D., au poste de président et directeur des opérations (COO), avec effet immédiat. Dans ce nouveau rôle, le Dr Trimarchi sera chargé de l'excellence opérationnelle, de la planification stratégique et du succès global de l'entreprise, reportant directement au PDG Neil Kumar, Ph.D. Il dirigera des activités interfonctionnelles pour développer une opération centralisée tout au long du portefeuille de projets avancés, en mettant l'accent sur l'efficacité, la rigueur et l'échelle.
Le Dr Trimarchi, qui a rejoint BridgeBio en 2018, a précédemment occupé le poste de directeur des produits et est membre du conseil d'administration de ML Bio Solutions, une filiale de BridgeBio. Son expérience antérieure comprend des rôles chez Regeneron Pharmaceuticals et Goldman Sachs. Le PDG Kumar a loué l'approche centrée sur le patient du Dr Trimarchi et sa prise de décision fondée sur les données, exprimant son enthousiasme pour la croissance continue et l'impact sur les patients sous sa direction.
BridgeBio Pharma (Nasdaq: BBIO) hat Thomas Trimarchi, Ph.D., zum Präsidenten und Chief Operating Officer (COO) ernannt, mit sofortiger Wirkung. In dieser neu geschaffenen Position wird Dr. Trimarchi die operative Exzellenz, strategische Planung und den allgemeinen Geschäftserfolg vorantreiben und direkt an CEO Neil Kumar, Ph.D. berichten. Er wird funktionsübergreifende Aktivitäten leiten, um einen zentralisierten Betrieb entlang des späten Pipeline-Portfolios zu entwickeln, mit einem Fokus auf Effizienz, Strenge und Skalierung.
Dr. Trimarchi, der 2018 zu BridgeBio kam, war zuvor Chief Product Officer und ist Mitglied des Vorstands von ML Bio Solutions, einem Tochterunternehmen von BridgeBio. Zu seinen früheren Erfahrungen gehören Positionen bei Regeneron Pharmaceuticals und Goldman Sachs. CEO Kumar lobte Trimarchis patientenorientierten Ansatz und datengestützte Entscheidungsfindung und äußerte sich enthusiastisch über das anhaltende Wachstum und den Einfluss auf Patienten unter seiner Führung.
- Appointment of an experienced internal candidate as President and COO
- Focus on operational excellence and strategic planning in late-stage pipeline
- Potential for improved efficiency and scalability in operations
- None.
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D.
In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized operation across the late-stage pipeline prioritizing efficiency, rigor, and scale.
“I’m thrilled to partner with Tom in his new role, and excited to continue to learn from him. Tom thinks independently, puts patients first, understands that every minute counts for the patients we serve, and lets science and data dictate his decision-making,” said Dr. Kumar. “He has been a tremendous part of building BridgeBio into what it is today, and I look forward to seeing his continued growth as a leader enable us to have ever-better impact on patients.”
Dr. Trimarchi has served in roles of increasing responsibility since joining BridgeBio in 2018, most recently as the Chief Product Officer. He is also a board member of ML Bio Solutions, a BridgeBio affiliate focused on developing BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), since November 2021. Prior to joining the company, Dr. Trimarchi worked at Regeneron Pharmaceuticals, Inc., and Goldman Sachs after receiving his Ph.D. in Molecular Oncology and Immunology from New York University.
“I am inspired every day by the work the teams are doing at BridgeBio to serve patients and families impacted by genetic diseases. The BridgeBio team is deeply passionate about the meaningful work they are doing to create and deliver transformative medicines with a patients-first mindset,” said Dr. Trimarchi. “I feel lucky to be stewarding our mission alongside Neil and Brian. We are just getting started on delivering life-changing treatments for as many patients as possible.”
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
FAQ
Who is the new President and COO of BridgeBio Pharma (BBIO)?
What are Thomas Trimarchi's responsibilities as President and COO at BridgeBio (BBIO)?
What was Thomas Trimarchi's previous role at BridgeBio (BBIO)?
How might Thomas Trimarchi's appointment impact BridgeBio's (BBIO) operations?
